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ABSTRACT The EarlyCDT-Lung test is a high-specificity blood-based autoantibody biomarker that could
contribute to predicting lung cancer risk. We report on the results of a phase IV biomarker evaluation of
whether using the EarlyCDT-Lung test and any subsequent computed tomography (CT) scanning to identify
those at high risk of lung cancer reduces the incidence of patients with stage III/IV/unspecified lung cancer
at diagnosis compared with the standard clinical practice at the time the study began.
The Early Diagnosis of Lung Cancer Scotland (ECLS) trial was a randomised controlled trial of 12208
participants at risk of developing lung cancer in Scotland in the UK. The intervention arm received the
EarlyCDT-Lung test and, if test-positive, low-dose CT scanning 6-monthly for up to 2 years. EarlyCDT-Lung
test-negative and control arm participants received standard clinical care. Outcomes were assessed at 2 years
post-randomisation using validated data on cancer occurrence, cancer staging, mortality and comorbidities.
At 2 years, 127 lung cancers were detected in the study population (1.0%). In the intervention arm, 33
out of 56 (58.9%) lung cancers were diagnosed at stage III/IV compared with 52 out of 71 (73.2%) in the
control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% CI 0.41–0.99). There were
nonsignificant differences in lung cancer and all-cause mortality after 2 years.
ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation)
and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of
a stage shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the
EarlyCDT-Lung test adds anything to the emerging standard of low-dose CT.
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Introduction
The 5-year lung cancer mortality rates of 80–90% remain unacceptably high and the UK’s survival rate is
poor by international comparisons [1]. To improve the poor prognosis, methods are needed that detect
lung cancer at an earlier stage, when it is more likely to be treated with curative intent. Several clinical
trials have reported that low-dose computed tomography (LDCT) screening can reduce lung cancer
mortality by ∼20% [2–5]. Most recently, the NELSON trial reported a 24% reduction in lung cancer
mortality from screening after 10 years of follow-up of 13131 males [4]. However, no difference in
all-cause mortality was demonstrated in NELSON nor in other large trials to date with follow-up >5 years,
including the US-based National Lung Screening Trial [3–9]. That LDCT screening can reduce lung
cancer mortality has provided impetus to consider national screening programmes for the early detection
of lung cancer. However, the widespread adoption of LDCT screening will likely remain limited by
resource constraints and concerns about overdiagnosis [10]. Cost-effective national screening programmes
in the UK are likely to have to take a more targeted approach to LDCT. A biomarker test could potentially
play a role in identifying those most at risk and who have most to gain from a targeted approach [11].
The EarlyCDT-Lung test is an ELISA that measures seven autoantibodies, each with individual specificity for
the following tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2.
Autoantibodies can be detected in peripheral blood in patients with solid tumours up to 3–4 years before
symptomatic presentation, although it is not yet clear how long autoantibodies continue to be present once
triggered [12, 13]. In clinical studies of symptomatic lung cancer and a high-risk cohort study, the
EarlyCDT-Lung test has demonstrated a specificity of 91% and sensitivity of 37–41% [14, 15]. The Early
Diagnosis of Lung Cancer Scotland (ECLS) trial was a phase IV (prospective screening) biomarker
evaluation that addressed the question: “Does using the EarlyCDT-Lung test to identify those at high risk of
lung cancer and any subsequent CT scanning reduce the incidence of patients with late-stage lung cancer
(III and IV) or unclassified presentation at diagnosis, compared with standard clinical practice?”.
Methods
ECLS was a pragmatic randomised controlled trial involving 12208 participants recruited through general
practices and community-based recruitment strategies in Scotland in the UK [16]. Recruitment occurred
between April 2013 and July 2016, and follow-up was undertaken for 24 months after randomisation for
each participant. Adults age 50–75 years at increased risk of developing lung cancer compared with the
general population were eligible to participate. These were defined as current or former cigarette or tobacco
smokers with at least 20 pack-years, or with a history of smoking of <20 pack-years plus immediate family
history (mother, father, sibling or child) of lung cancer. Potential trial participants were identified from the
electronic medical records of general practices that were located in the most socioeconomically deprived
areas in Scotland or they self-referred in response to a range of advertising methods. Trial participants had
no symptoms suggestive of current malignancy, terminal illness or immunosuppressant therapy and had an
Eastern Cooperative Oncology Group performance status of 0–2 at recruitment.
The study was conducted in accordance with the principles of Good Clinical Practice and the UK National
Research Governance Framework [17]. The University of Dundee and Tayside Health Board co-sponsored
the trial, which was registered at ClinicalTrials.gov with identifier NCT01925625. Institutional Review
Board approval was provided by the East of Scotland Research Ethics Committee (REC 13/ES/0024).
Funding for the trial was obtained from the Scottish Government and the test manufacturer Oncimmune
(Nottingham, UK). The trial was conducted in accordance with the protocol [16]; the protocol and the
statistical analysis plan are available in the supplementary material. An independent Trial Steering
Committee provided trial oversight. The report herein adheres to the CONSORT statement and Aarhus
guidelines for the reporting of clinical trials on early cancer diagnosis [18, 19].
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Randomisation and masking
All participants who gave informed consent provided a blood sample prior to randomisation. Participants
were then individually randomised, stratified by recruitment site (Tayside, Glasgow and Lanarkshire), and
minimised by age, sex and smoking status. Smoking cessation advice was offered in keeping with NHS
Scotland advice. Participants allocated to the intervention arm were tested with the EarlyCDT-Lung test. If
this was positive, they received a baseline chest radiograph (in order to prioritise access to CT for patients
with positive findings on chest radiography) and chest LDCT scan followed by 6-monthly LDCT scans up
to 24 months post-randomisation (supplementary table S1). Images from test-positive participants were
reviewed by a panel of experienced thoracic radiologists and respiratory physicians. Test-positive
participants were followed-up within the study or via the NHS care pathway (following the prevailing
Fleischner Society guidelines), whichever was most intensive [20]. Participants allocated to the control arm
and those who were test-negative received standard clinical care in the NHS in Scotland following national
guidelines for identification and management of symptoms suggestive of lung cancer with no further study
investigations [21].
Blood samples were processed according to the protocol (supplementary material) and Standard Operating
Procedures, consistent with relevant UK and US guidelines. The EarlyCDT-Lung test was performed on
0.5 mL plasma samples. All test-positive, and a random sample of test-negative and control arm
participants recruited between December 2013 and April 2015, were invited to complete study
questionnaires measuring psychological and smoking outcomes, the EuroQol-5D questionnaire, and health
service use (supplementary table S2). Invitation to complete the study questionnaires was done at 1, 3, 6
and 12 months for the test-negative and control arms, with additional questionnaire testing at 18 and
24 months for participants in the test-positive group. These results are reported elsewhere [22, 23].
With participant consent, validated data on cancer occurrence, mortality and comorbidities were obtained
from National Services Scotland, which is a high-quality health services data repository. These were linked
and analysed in the Dundee Health Informatics Centre Safe Haven.
Pathology and tumour staging reports were prepared by independent assessors who were blinded to the
allocation status of participants. Staging data were taken from the Scottish Cancer Registry (SMR06) [24].
The primary outcome variable extracted from SMR06 was the first occurrence of all diagnoses starting
with the International Statistical Classification of Diseases and Related Health Problems 10th Revision
codes C33 (primary malignant neoplasm of trachea) and C34 (bronchus or lung). Where more than one
lung cancer tumour was present at diagnosis, the most advanced tumour was used for classification of
disease. To determine staging, reported clinical and pathological “T (tumour), N (node), M (metastasis)”
were used with pathological staging taking precedence when present by data analysts blinded to allocation
status. Lung tumour histology was coded in accordance with the International Classification of Diseases
for Oncology Third Edition and lung cancer staging was determined using the TNM Classification of
Malignant Tumours Seventh Edition [25].
Sample size
During study planning, the background rate of lung cancer was 187 per 100000 per year for people aged
50–75 years in Scotland. Those in the most deprived quintile were associated with an increased risk of
1.8 times compared with the middle quintile of deprivation [26, 27]. The ECLS study population was
selected using similar entry criteria as the Mayo screening study in the USA [26]. The precise baseline rate
of stage III/IV presentation for the high-risk population envisaged in this study was uncertain, as was the
size of the reduction in stage III/IV presentation likely to be achieved through use of the EarlyCDT-Lung
test. Based on the literature and expert opinion, we estimated a stage III/IV presentation rate of 1200 per
100000 per year in the control group, resulting in an estimated 2.4% prevalence rate over the 2-year
follow-up period. Using this estimate and 85% power at 5% significance (two-sided), we wanted to be able
to detect a 35% reduction in the rate of stage III/IV presentation in the intervention arm. Based on
discussion with a range of stakeholders, this was considered likely to be sufficiently clinically significant to
influence practice. Taken together, we estimated the event rate over the 2 years of follow-up at 120 events
in the control arm and 78 events in the intervention arm, and required a sample size of n=5000 per arm.
The protocol allowed for the sample size to be modified if the observed event rate proved to be markedly
different from the modelled estimates. The sample size was revised to 12000 in 2015, after recruitment of
approximately 8600 participants, when it appeared that, while still meeting trial eligibility criteria, our
initial assumption of the rate of stage III/IV presentation had been overestimated. The increase in sample
size was achieved by adding an extra recruitment centre (Lanarkshire) and extending the recruitment
period. The revised power was 85% at 5% significance (two-sided) to detect a 35% reduction in stage III/
IV lung cancer, based on a rate of 600 per 100000 with a 3-year recruitment period and 2 years of
follow-up, with no loss to follow-up anticipated.
https://doi.org/10.1183/13993003.00670-2020 3
LUNG CANCER | F.M. SULLIVAN ET AL.
Statistical analysis
The primary analysis compared the rate of stage III/IV lung cancer within 2 years of randomisation
between the intervention and control arms. The analyses followed the intention-to-treat principle. Cox
proportional hazards models were used to estimate the hazard ratio. One participant who withdrew
consent for use of their data was excluded from analysis. The models were adjusted for age, sex, smoking
history, socioeconomic status and general practice.
Similar methodology was used to analyse the secondary outcomes of mortality rates. Further analysis
compared the outcomes of those in the intervention arm with a positive test, those in the intervention arm
with a negative test and those in the control arm. Comparisons of proportions were carried out using
Fisher’s exact test due to the small number of events. Poisson regression models (adjusting for follow-up
time when necessary) were used to investigate other clinical outcomes. Specificity and sensitivity were
calculated, but these are estimated values as the true figures are not estimable for early stage and late stage
separately. This is because the test-positives received a more intensive intervention than the test-negatives
and in a prospective study cancer status is unknown most of the time. The full statistical analysis plan can
be found in the supplementary material.
A within-trial model-based cost-effectiveness analysis was conducted, estimating the cost per stage I/II
lung cancer case detected comparing the intervention with the control arm. Diagnostic costs were included
for all groups. A model-based approach was taken for two reasons: 1) prevalence of lung cancer during the
trial was different between arms (our model assumed the same prevalence in both arms) and 2) data about
resource use for detection were only available for test-positive participants (n=598) during the trial,
therefore resource use was modelled. Full assumptions and parameters used in the model are presented in
the supplementary material. Briefly, detection resources comprised the EarlyCDT-Lung test, monitoring
tests and confirmatory diagnostic tests. The outcome was number of stage I/II lung cancers detected
within the 2-year follow-up. Treatment costs are not included in this within-trial cost-effectiveness
analysis.
Results
Characteristics of the participants
A total of 77077 invitation letters were sent to people fulfilling the medical record search criteria from 166
general practices; 16268 people responded. An additional 2389 potential participants self-referred in
response to advertising. 12241 were invited to an in-person screening appointment and 12215 were
randomised. The recruitment rate of people identified as potential study participants from general practice
records was 13.4% (10352 out of 77077). Six participants were excluded post-randomisation but prior to
receiving imaging because of ineligibility. One participant who withdrew consent for use of their data was
excluded from analysis, leaving 12208 participants. Participant characteristics were balanced between arms
(table 1). 51.8% of participants lived in the two most deprived quintiles, the mean±SD age at recruitment
was 60.5±6.58 years and the mean±SD pack-years smoked was 38.2±18.58. The incidence rate of lung
cancer in the trial population, as determined from cancer registry data, was 520 per 100000 per annum
(0.52%).
Adherence to protocol
We accessed the records of 99.9% of the study population; the CONSORT flowchart (figure 1) presents
the end-point ascertainment in the intervention and control arms. The CONSORT statement is available
in the supplementary material.
Follow-up was performed using a national, closed administrative data system for 24 months after
individual randomisation or to death if within the follow-up period. We also checked national prescribing
and inpatient/outpatient data systems for activity relating to trial participants in the 2-year
post-randomisation follow-up period. We confirmed health service contacts in the 2-year follow-up for 10
973 (89.9%) of the participants: 5489 in the intervention arm and 5484 in the control arm. When the 1235
patients who did not record health service contacts during this period were removed from the analysis, the
key findings were unchanged (data pack S3 in the supplementary material).
Results of testing
The results of the primary analysis are presented in table 2 and figure 2. 9.8% (598 out of 6087) of
participants in the intervention arm had a positive EarlyCDT-Lung test and 3.0% (n=18) of these had a
confirmed case of lung cancer within 2 years. In the test-negative arm, 0.7% (n=38) had confirmed lung
cancers. For the intervention group as a whole, 0.92% (n=56) had confirmed lung cancer within 2 years.
In the control arm, 1.16% (n=71) had confirmed lung cancer within 2 years. The percentage of stage III/
IV/unspecified lung cancer diagnosis in the intervention and control arm was 0.5% (33 out of 6087) and
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0.8% (52 out of 6121), respectively. The absolute risk reduction in stage III/IV/unspecified lung cancer
diagnosis was 0.3% (95% CI 0.01–0.6). The number of participants to be screened to prevent one stage III/
IV/unspecified lung cancer diagnosis was 325 (95% CI 13–637) and the hazard ratio for stage III/IV
presentation was 0.64 (95% CI 0.41–0.99; p=0.0432) (data pack S2 in the supplementary material).
Although we did not perform LDCT on all study subjects, the estimated test performance characteristics
using cancer registry data after 2 years of follow-up as the reference standard are described in table 3. The
EarlyCDT-Lung test had an estimated sensitivity of 52.2% (95% CI 30.6–73.2%) for stage I/II disease and
18.2% (95% CI 7.0–35.5%) for stage III/IV disease, and specificity of 90.3% (95% CI 89.6–91.1%) for stage
I/II disease and 90.2% (95% CI 89.4–91.0%) for stage III/IV disease. The positive predictive value was
2.0% (95% CI 1.0–3.5%) for stage I/II disease and 1.0% (95% CI 0.4–2.2%) for stage III/IV disease, and
the negative predictive value was 99.8% (95% CI 99.6–99.9%) for stage I/II disease and 99.5% (95% CI
99.3–99.7%) for stage III/IV disease in the population studied.
Figure 3 shows the secondary outcomes of lung cancer and all-cause mortality at 2 years, and
demonstrates divergence after the first year of follow-up. In the intervention arm, there were fewer events
than in the control arm for all-cause mortality. There were nonsignificant differences in lung cancer
mortality (intervention arm 17 out of 6087 (0.28%) versus control arm 24 out of 6121 (0.39%)) and
all-cause mortality (intervention arm 87 out of 6087 (1.43%) versus control arm 108 out of 6121 (1.76%))
after 2 years. Participants in the intervention arm were diagnosed with lung cancer on average 87.3 days
earlier (mean 303.0 (95% CI 214.9–364.0) days) compared with the control arm (mean 390.3 (95% CI
340.6–440.1) days) (data pack S3 in the supplementary material).
The cost per early case (stage I/II) detected after 2 years was GBP116000 (95% CI GBP54900 to dominated, i.e.
screening using the EarlyCDT-Lung test would be more costly and less effective than the control arm)
(supplementary table S3). Sensitivity analyses were conducted varying prevalence and test costs; results indicate
that cost-effectiveness was most affected by changes in prevalence. More detailed analyses are planned to
extrapolate the cost per case detected to a full lifetime cost per quality-adjusted life year (QALY) gained
analysis, including stage-specific treatment costs (supplementary material). As not all required data are available
at the time of writing, comprehensive cost-effectiveness analyses will be presented in a subsequent article.
TABLE 1 Selected baseline characteristics of the trial participants
Intervention (EarlyCDT-Lung test) Control (standard clinical care)
Subjects 6088 6121
Age at randomisation years
50–54 1393 (22.9) 1409 (23.0)
55–59 1562 (25.7) 1531 (25.0)
60–64 1300 (21.4) 1318 (21.5)
65–69 1179 (19.4) 1203 (19.7)
70–75 654 (10.7) 660 (10.8)
Sex
Male 3095 (50.8) 3129 (51.1)
Female 2993 (49.2) 2992 (48.9)
SIMD quintile
1 (most deprived) 1751 (28.8) 1726 (28.2)
2 1431 (23.5) 1420 (23.2)
3 1108 (18.2) 1121 (18.3)
4 966 (15.9) 1002 (16.4)
5 782 (12.8) 792 (12.9)
No information 50 (0.8) 60 (1.0)
Smoking status
Current smoker 3199 (52.5) 3178 (51.9)
Ex-smoker 2889 (47.5) 2943 (48.1)
Quit ⩾1 week 2207 (36.3) 2283 (37.3)
Quit ⩾6 months 1998 (32.8) 2083 (34.0)
Pack-years 38.4±18.7 38.0±18.5
Family history 1550 (25.5) 1614 (26.4)
Comorbidity
COPD 306 (5.0) 287 (4.7)
Data are presented as n or n (%). SIMD: Scottish Index of Multiple Deprivation; COPD: chronic obstructive
pulmonary disease.
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Adverse events
Five adverse events, as defined in the protocol as being directly related to the intervention (collection of
blood sample), were reported and all were considered minor. For those in the intervention arm, there was
one injection site haematoma, one panic attack and one pre-syncope. In the control arm there were two
episodes of syncope.
Discussion
This is the first trial conducted as a phase IV evaluation of a blood-based biomarker panel for lung cancer.
The results show a significant decrease in the incidence of advanced stage disease, thereby meeting the













  Primary care (n=10 352)
  Self-referral (n=1889)
Not proceeding (n=26)
Allocated to intervention (n=6088)
Randomised (n=12 209)
Requesting contact (n=18 657) Not proceeding (n=6416):
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  Ineligible error (n=1)
  Randomisation error (n=1)
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Allocated to control (n=6121)
Test-negative (n=5489)
24-month cancer diagnosis record
(n=12 208)
Analysed (n=12 208):
  Intervention (n=6087)
  Control (n=6121)
Withdrew consent (n=1)
FIGURE 1 CONSORT flowchart. CT: computed tomography.
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III/IV lung cancer diagnosis for those in the intervention arm was 0.3%. For those participants given a
lung cancer diagnosis in the study period, there was a 14.3% absolute risk reduction (33 out of 56 versus
52 out of 71) in stage III/IV lung cancer presentation in the intervention arm. After the short follow-up
period of 2 years, there were nonsignificant reductions in lung cancer mortality: 29.2% in relative risk
(control 24 versus intervention 17) and 19.4% in all-cause mortality (control 108 versus intervention 87).
Community-based trials such as ECLS are more likely to produce generalisable results than those
conducted in academic health centres, which often recruit from a more tightly selected population [28].
Strengths of our trial include community recruitment with a high proportion of participants recruited by
their general practitioners from the two most socioeconomically deprived quintiles (51.8%) of the Scottish
population, integration with a national healthcare system providing whole-population care, a high
end-point ascertainment rate (>99.9%) and the intention-to-treat analysis.
The lung cancer diagnosis rate (1%) was lower than we anticipated when planning the study and lower
than might be expected from other studies using LDCT. Therefore, our approach, in contrast to LDCT,
may have missed early-stage lung cancers. Our follow-up period of 2 years was short and cases will
continue to emerge as the study final results become available. Another potential contributor to the lower
rate of diagnosis may be the “healthy volunteer” effect, which may have led to a higher rate of recruitment
of the healthiest among the at-risk population meeting our inclusion criteria [29]. It is worth noting that
TABLE 2 Stage of lung cancer at diagnosis in the intervention and control arms
Intervention Control (standard clinical care)
Test-positive Test-negative
Subjects 598 5489 6121
Stage
I 10 (1.7) 7 (0.1) 9 (0.1)
II 2 (0.3) 4 (0.1) 10 (0.2)
III 3 (0.5) 12 (0.2) 17 (0.3)
IV 3 (0.5) 15 (0.3) 28 (0.5)
Unspecified 0 (0.0) 0 (0.0) 7 (0.1)
No lung cancer 580 (97.0) 5451 (99.3) 6050 (98.8)














Time since randomisation days
Control group
Intervention group
FIGURE 2 Primary outcome: diagnosis of stage III/IV/unspecified lung cancer 2 years after randomisation in
the intervention and control arms.
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even with a lower rate of lung cancer, those in the intervention arm were at a statistically significant and
clinically important reduced risk of stage III/IV presentation. The results of this study are not directly
comparable to those using a validated questionnaire before LDCT [30]. A direct comparison of both
methods would need to be undertaken to determine how a biomarker test compares to a questionnaire
followed by LDCT. A control arm involving CT screening would have provided evidence comparing the
US Preventive Task Force guidelines against a “biomarker first” approach, but CT screening was not
available when the ECLS trial started and remains unavailable in many health systems, including the UK.
The finding that there were more lung cancers in the control arm (71 versus 56 in the intervention arm)
was also unexpected as CT screening trials usually report more cancers diagnosed in the intervention arm.
We consider that there are four potential reasons for this. First, as discussed earlier, we may have not
TABLE 3 Estimated EarlyCDT-Lung test performance characteristics 6 months, 1 year and 2 years after randomisation





Stage of lung cancer 6 months after
randomisation (post hoc)
I/II 7 (1.2) 2 (0.0) 77.8 (40.0–97.2) 90.3 (89.5–91.0) 1.2 (0.5–2.4) 100.0 (99.9–100.0)
III/IV 5 (0.8) 8 (0.2) 38.5 (13.9–68.4) 90.2 (89.5–91.0) 0.8 (0.3–1.9) 99.9 (99.7–99.9)
I–IV 12 (2.0) 10 (0.2) 54.6 (32.2–75.6) 90.3 (89.6–91.1) 2.0 (1.0–3.5) 99.8 (99.7–99.9)
Stage of lung cancer 1 year after
randomisation (post hoc)
I/II 9 (1.5) 4 (0.1) 69.2 (38.6–90.9) 90.3 (89.5–91.0) 1.5 (0.7–2.8) 99.9 (99.8–100.0)
III/IV 6 (1.0) 14 (0.2) 30.0 (11.9–54.3) 90.2 (89.5–91.0) 1.0 (0.4–2.2) 99.7 (99.6–99.9)
I–IV 15 (2.5) 18 (0.3) 45.5 (28.1–63.6) 90.4 (89.6–91.1) 2.5 (1.4–4.1) 99.7 (99.5–99.8)
Stage of lung cancer 2 years after
randomisation
I/II 12 (2.0) 11 (0.2) 52.2 (30.6–73.2) 90.3 (89.6–91.1) 2.0 (1.0–3.5) 99.8 (99.6–99.9)
III/IV 6 (1.0) 27 (0.5) 18.2 (7.0–35.5) 90.2 (89.4–91.0) 1.0 (0.4–2.2) 99.5 (99.3–99.7)
I–IV 18 (3.0) 38 (0.7) 32.1 (20.3–46.0) 90.4 (89.6–91.1) 3.0 (1.8–4.7) 99.3 (99.1–99.5)
Data are presented as n, n (%) or % (95% CI). Absolute risk reduction of late-stage lung cancer diagnosis 2 years after randomisation was



















FIGURE 3 Secondary outcomes: mortality 2 years after randomisation in the intervention and control arms.
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diagnosed all cases of lung cancer. Second, although treatment arms were well balanced due to
randomisation, there may be differences between arms in unmeasured risk factors, such as asbestos
exposure [31]. Third, false reassurance in the test-negative arm (leading to risk-reduction behaviours in
those receiving the EarlyCDT test) may also be a potential explanation. A recent systematic review found
that negative test results are unlikely to cause false reassurance, anxiety or a change in health-related
behaviours; hence, we consider it unlikely that false reassurance had a substantial impact on lung cancer
presentation in those with negative test results [32]. Finally, the observed numerical difference is not
statistically significant and could be due to chance (p=0.2)
We have presented a short-term within-trial analysis of cost-effectiveness data. A recent study has
suggested that the use of an autoantibody test in patients with pulmonary nodules is a cost-effective use of
healthcare resources [33]. The base case cost per QALY gained of GBP116000 is a within-trial estimate,
and does not include long-term costs of treatment and survival beyond the trial. Longer-term analyses will
employ a model to link the short-term outcomes measured within the trial to longer-term health impacts
(e.g. morbidity and mortality), and will consider the longer-term impact of early detection and treatment
on the cost per QALY gained in the context of more effective and expensive therapies.
The seven autoantibodies to the tumour-associated antigen panel of the EarlyCDT-Lung test demonstrated
high specificity (90.4%) and moderate sensitivity (32.1%) for detecting lung cancer at 2 years. The moderate
sensitivity of the test at 2 years may be due to tumour-induced suppression of immune responses that lead to
less autoantibody production and detection [34]. The study measured the EarlyCDT-Lung test only once at
baseline and so does not address the frequency at which the test might be repeated. A previous report
showed that in patients with lung nodules the EarlyCDT-Lung test enhanced the positive predictive power of
nodule-based risk assessment for the detection of lung cancer [35]. The high specificity of the
EarlyCDT-Lung test could be used in combination with LDCT, which demonstrates high sensitivity, to
ensure a high detection rate of stage I/II lung cancer cases. Recent developments in the use of artificial
intelligence in imaging and other biomarkers are also likely to be important [36].
In conclusion, ECLS demonstrates that blood-based biomarker panels, such as the EarlyCDT-Lung test,
followed by LDCT can detect stage I/II lung cancer. Follow-up analyses will be performed after 5 and
10 years, although we recognise that the absolute lung cancer incidence would be higher than that detected
due to deaths from other causes. Further investigation in large, community-based studies will be required
to determine the long-term impact of performing the EarlyCDT-Lung test with LDCT on mortality,
cost-effectiveness, the level of risk that should be targeted, the time interval between tests and how to
improve the engagement of people at the highest risk [37].
Data availability: Will individual deidentified participant data be shared: yes. What data will be shared: all individual
participant data and blood samples collected during the trial, after deidentification. What additional, related documents
will be available: study protocol, statistical analysis plan. When will data become available and for how long: data are
currently available with no fixed end date. By what access criteria data will be shared (including with whom, for what
types of analyses and by what mechanism): applications should be made to the ECLS Data and Sample Access
Committee (Fiona Hogarth, Co-Director of Tayside Clinical Trials Unit; E-mail: f.j.hogarth@dundee.ac.uk). Applicants
must obtain prior ethical and regulatory approvals for their work.
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